until the US regulator cleared Apellis' complement C3 inhibitor Syfovre (pegcetacoplan) in 2023. That was followed shortly after by the FDA approval of Astellas' C5 inhibitor Izervay (avacincaptad ...

In a report released on March 5, Seiji Wakao from J.P. Morgan maintained a Hold rating on Astellas Pharma (ALPMF – Research Report), with a price target of Yen1,700.00. The company’s shares ...

With the power of robotics and the personalized medicine expertise of one of Japan's top drugmakers, Astellas Pharma and ...

Astellas and Yaskawa are establishing a joint venture for the development of a cell therapy product manufacturing platform ...

Astellas Pharma and Yaskawa Electric have signed a definitive agreement to establish a joint venture aimed at advancing cell therapy manufacturing through automation. According to Astellas, the ...

The agreement—powered by YASKAWA's Maholo robot—aims to address challenges in production and commercialization while offering ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Astellas has won a reprieve in its ... company trying to bring a version of regadenoson to the US market. AmphaStar and Glenmark Pharma also claimed FDA approval for versions of the drug earlier ...

Continued progress with lead program, CX-2051 (EpCAM PROBODY® Topo-1 ADC), in Phase 1a study in advanced colorectal cancer with initial Phase ...

The JV will leverage the dual-arm robot Maholo, developed by Yaskawa subsidiary the Robotic Biology Institute.

Astellas Pharma (OTCPK:ALPMY) and YASKAWA Electric signed a definitive agreement to establish a joint venture for the development of a cell therapy product manufacturing platform utilizing the ...